Morgan Stanley
ARLZ

Morgan Stanley’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Morgan Stanley’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-41,977
Closed -$14K – 7036
2018
Q2 		$14K Sell
41,977
-32,841
-44% -$26.9K ﹤0.01% 6236
2018
Q1 		$113K Buy
74,818
+13,010
+21% +$22.7K ﹤0.01% 5668
2017
Q4 		$88K Buy
61,808
+14,021
+29% +$23K ﹤0.01% 5676
2017
Q3 		$110K Sell
47,787
-55,168
-54% -$73.8K ﹤0.01% 5547
2017
Q2 		$139K Buy
102,955
+2,611
+3% +$3.77K ﹤0.01% 5503
2017
Q1 		$215K Sell
100,344
-86,433
-46% -$325K ﹤0.01% 5298
2016
Q4 		$823K Buy
186,777
+115,486
+162% +$548K ﹤0.01% 4614
2016
Q3 		$346K Buy
71,291
+38,771
+119% +$177K ﹤0.01% 4742
2016
Q2 		$107K Sell
32,520
-314
-1% -$1.19K ﹤0.01% 5217
2016
Q1 		$116K Buy
+32,834
New +$169K ﹤0.01% 5248

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Morgan Stanley's ARLZ Position: Q3 2018 in Review

Morgan Stanley sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 41,977 shares — an estimated $14K sold.

Morgan Stanley first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $823K in Q4 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Morgan Stanley reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Morgan Stanley sold 41,977 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $14K.
  • Morgan Stanley first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
  • Morgan Stanley's Aralez Pharmaceuticals Inc. position peaked at $823K in Q4 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Morgan Stanley's 13F filing for Q3 2018, filed 14 Nov 2018.